GE HealthCare beats Q3 profit estimates
GE HealthCare Technologies Inc. (GEHC) said Tuesday it had net income of $375 million, or 83 cents a share, for the third quarter, down from $487 million, or $1.07 a share, in the year-earlier period. Adjusted per-share earnings came to 99 cents, ahead of the 90 cent FactSet consensus. Revenue rose 5% to $4.8 billion to match the FactSet consensus. The company, which was spun out of General Electric Co. (GE) in January, said revenue at its imaging segment rose 5% to $2.6 billion, while ultrasound revenue fell 1% to $815 million. Patient care solutions revenue rose 9% to $764 million and pharmaceutical diagnostics revenue rose 13% to $589 million. The company raised the low end of its full-year guidance and now expects adjusted EPS of $3.75 to $3.85, versus prior guidance of $3.70 to $3.85. The stock was not yet active premarket but has gained 8% in the year to date, while the S&P 500 has gained 8.5%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-31-23 0632ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks